Focus Partners Advisor Solutions’s Pacira BioSciences PCRX Stock Holding History

Focus Partners Advisor Solutions’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,900	Closed	-$404K	–	399
2023 Q1	$404K	Sell	9,900 -4,500	-31%	-$179K	0.03%	232
2022 Q4	$556K	Sell	14,400 -3,882	-21%	-$189K	0.04%	177
2022 Q3	$972K	Buy	18,282 +4,046	+28%	+$225K	0.06%	150
2022 Q2	$830K	Sell	14,236 -1,001	-7%	-$65.6K	0.07%	136
2022 Q1	$1.16M	Buy	+15,237	New	+$1.02M	0.12%	103

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Focus Partners Advisor Solutions's PCRX Position: Q2 2023 in Review

Focus Partners Advisor Solutions sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 9,900 shares — an estimated $404K sold.

Focus Partners Advisor Solutions first reported a position in PCRX in Q1 2022 and held it in 5 quarters. The position peaked at $1.16M in Q1 2022. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

Focus Partners Advisor Solutions reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
Focus Partners Advisor Solutions sold 9,900 Pacira BioSciences shares in Q2 2023, an estimated $404K.
Focus Partners Advisor Solutions first reported a position in Pacira BioSciences in Q1 2022 and held it in 5 quarters.
Focus Partners Advisor Solutions's Pacira BioSciences position peaked at $1.16M in Q1 2022.
258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2023, filed 14 Aug 2023.